• Users Online: 21
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2018  |  Volume : 3  |  Issue : 1  |  Page : 1-7

Effect of simvastatin on the transforming growth factor β1, fibroscan scores, and aspartate transaminase to platelet index ratio patients with Liver Cirrhosis


Gastroenterohepatologi, Division of Internal Medicine Department, Medical Faculty, Universitas Sebelas Maret, Indonesia

Correspondence Address:
N A Prabowo
Gastroenterohepatologi, Division of Internal Medicine Department, Medical Faculty, Universitas Sebelas Maret
Indonesia
Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

Background: Cirrhosis of the liver is the liver disorder marked fibrosis and abnormal liver architecture. Treatment of liver cirrhosis, among others, is to reduce fibrogenesis. Simvastatin as an anti-fibrotic among others, by a mechanism reduce the activity of hepatic stellate cell of the liver, reduce cell proliferation liver stelat, increases the production of nitric oxide and decrease vascular resistance in the liver cirrhosis. Aim: This research to determine effect of simvastatin on the transforming growth factor β1, fibroscan scores, and aspartate transaminase to platelet index ratio patients with liver cirrhosis. Methods: This study is a randomized experiment, a sample of 30 people, divided into a control group given a placebo and the treatment given simvastatin 20 mg / day orally for 4 weeks. Before and after treatment measured levels of TGF β1, FibroScan score, and a score of APRI. Statistical analysis using SPSS 22 for windows. Two different test mean using parametric tests (independent t test, paired t test) and if the data is normally distributed variable or non-parametric tests (Mann-Whitney / Wilcoxon Signed Rank Test). P significant if p <0.05. Results: The results showed that the administration of simvastatin 20 mg for 4 weeks will reduce levels TGF β1 (20,98+7,80 μg/dl pretreatment, 16,20+5,50μg/dl post treatment; p=0,013), reduce fibroscan scores (22,29+14,65 kpa pretreatment, 13,61+4,02 kpa post treatment; p=0,049) and reduce APRI scores (40,13+41,28 pretreatment, 23,41+17,61 post treatment; p=0,002). Conclusion: This study demonstrated that administration Simvastatin will be reduced levels of the transforming growth factor β1, fibroscan scores, and aspartate transaminase to platelet index ratio patients with liver cirrhosis.


[PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed76    
    Printed4    
    Emailed0    
    PDF Downloaded22    
    Comments [Add]    

Recommend this journal